Cassidy J
Institute of Medical Sciences, Aberdeen University, UK.
Int J Clin Pract. 2000 Jul-Aug;54(6):399-402.
Oxaliplatin is a novel platinum analogue which has wide spectrum anti-cancer activity in in vitro systems. It has distinct biochemical, pharmacological and cytotoxic properties which are different from those of cisplatin and carboplatin. Importantly, it appears to have distinct mechanisms of resistance such that traditionally platinum insensitive tumour types may be susceptible to oxaliplatin. Most notable in this regard is the activity of this agent which has been demonstrated in colorectal cancer. This review concentrates on this aspect of oxaliplatin. Oxaliplatin has modest activity as a single agent in advanced colorectal cancer compared with other novel agents in this disease. However, there appears to be a powerful synergy between oxaliplatin and 5-fluorouracil. Thus, when given together, response rates of over 50% are consistently observed. The combination has now been extensively tested in this disease and has recently led to the regulatory approval for marketing of oxaliplatin in this condition.
奥沙利铂是一种新型铂类类似物，在体外系统中具有广谱抗癌活性。它具有与顺铂和卡铂不同的独特生化、药理和细胞毒性特性。重要的是，它似乎具有独特的耐药机制，使得传统上对铂不敏感的肿瘤类型可能对奥沙利铂敏感。在这方面最值得注意的是该药物在结直肠癌中的活性。本综述集中于奥沙利铂的这一方面。与该疾病中的其他新型药物相比，奥沙利铂作为单一药物在晚期结直肠癌中活性一般。然而，奥沙利铂与5-氟尿嘧啶之间似乎存在强大的协同作用。因此，当联合使用时，始终观察到超过50%的缓解率。这种联合用药现已在该疾病中进行了广泛测试，最近已获得监管部门批准在这种情况下销售奥沙利铂。
